ACR Updates: COVID-19

 

Latest COVID-19 News

ACR COVID-19 Town Hall: COVID-19 Vaccination, Immunosuppression and Rheumatic Disease - Wednesday, August 4

Join us on August 4 from 7:00–8:00 PM ET for the upcoming ACR town hall, COVID-19 Vaccination, Immunosuppression and Rheumatic Disease. The town hall will focus on the COVID-19 vaccines' effectiveness in immunosuppressed and rheumatic disease patients. Find out what we are learning from real-world data collection efforts and ask questions of the expert panel. The ACR panel consists of Marcus Snow, MD, Kwas Huston, MD, Alfred Kim, MD, PhD, and Jean Liew, MD, MS. We will also be joined by Michael R. Anderson, MD, MBA, FAAP, FCCM, FAARC, a key leader on the COVID-19 monoclonal antibody therapeutics team who has been deployed with the federal COVID-19 monoclonal antibody administration team.
Register for Town Hall

ACR COVID-19 Town Hall: Building Vaccine Confidence in Rheumatic Disease Patients - Thursday, May 13

The ACR hosted a virtual town hall for the rheumatology community on May 13. The town hall addressed the reasons some rheumatic disease patients, including those in communities of color and underserved communities, are hesitant to take the COVID-19 vaccine. The discussion included best practices, resources, and talking points that rheumatology providers can use to provide information to their patients.
Watch Town Hall Recording
Download COVID-19 Vaccination Resources for Patients - June 3, 2021
Download Vaccine Infographic for Patients - June 7, 2021

COVID-19 Vaccine Clinical Guidance

The ACR has developed new guidance for rheumatology providers on the use of the COVID-19 vaccines for patients with rheumatic and musculoskeletal diseases. All recommendations are based on current knowledge and will be revised as circumstances and evidence evolve.
Vaccine Clinical Guidance Summary - Recommendations updated June 19, 2021

See All Breaking COVID-19 News

 

Practice and Advocacy Resources

ACR COVID-19 practice and advocacy resourcesThe ACR’s COVID-19 Practice and Advocacy Task Force continues to work rapidly to provide support to you during this unprecedented time. You’ll find guidance documents that include approaches to drug shortages, support for telehealth, information about federal stimulus relief aid, and guidance for infusions. Working with experts in COVID-related topics, we are focused on developing meaningful information and resources to help guide you.
Practice and Advocacy Resources

COVID-19 Manufacturer Resources and Patient Assistance Programs  

 

New: COVID-19 Vaccine Clinical Guidance

ACR COVID-19 Vaccine Clinical GuidanceThe ACR has developed new guidance for rheumatology providers on the use of the COVID-19 vaccine for patients with rheumatic and musculoskeletal diseases (RMDs). All recommendations are based on current knowledge and will be revised as circumstances and evidence evolve.
COVID-19 Vaccine Clinical Guidance Summary - Recommendations updated June 19, 2021

ACR on Air Podcast with lead author, Jeffrey Curtis, MD, MPH 

ACR COVID-19 Vaccine Guidance Town Hall Recording

Press Release: ACR COVID-19 Vaccine Guidance Recommends Vaccination, Addresses Immunosuppressant Drugs & Patient Concerns

 

Clinical Guidance for Pediatric Patients

ACR COVID-19 clinical guidance for pediatric patients with rheumatic diseasesThe ACR has developed two new clinical guidance documents for pediatric patients in the context of the COVID-19 pandemic, including for the care of children with pediatric rheumatic disease, and for the management of inflammatory syndromes in children with recent or concurrent infections with SARS-CoV-2, specifically Multisystem Inflammatory Syndrome in Children (MIS-C). All recommendations are based on current knowledge and will be revised as circumstances and evidence evolve.
Clinical Guidance for Pediatric Patients

 

 

Clinical Guidance for Adult Patients with Rheumatic Diseases

ACR COVID-19 clinical guidance for patients with rheumatic diseasesThe ACR has developed clinical guidance for the care of adult patients with rheumatic diseases during the COVID-19 pandemic. Populations considered include patients with a documented COVID-19 infection, those who are stable following exposure to SARS-CoV-2 (but without known infection), and patients who are stable with no infection or exposure. The recommendations address various treatment options and provide general guidance, as well as direction for when to start, stop, or reduce medications. All recommendations are based on current knowledge and will be revised as circumstances and evidence evolve.
Clinical Guidance for Adult Patients with Rheumatic Diseases

 

Global Rheumatology Alliance

COVID-19 Global Rheumatology AllianceThe COVID-19 Global Rheumatology Alliance, a section of the American College of Rheumatology, is a provider-entered registry aiming to collect data on rheumatology patients with COVID-19 and hopes the information will provide guidance for rheumatology professionals when assessing and treating the infection in patients with rheumatic disease.
The Global Rheumatology Community’s Response to the Worldwide COVID-19 Pandemic  

Help Us Help Patients: Report a COVID-19 Case  

 

Questions and Feedback

Are you experiencing COVID-19 related drug shortages, practice issues, or any other problems? Share your comments and questions with us at COVID@rheumatology.org

Thank you to the corporate supporters of the ACR COVID-19 Emergency Response.

Updated July 22, 2021 at 9:30 AM ET

© 2021 American College of Rheumatology.  All rights reserved.  Website & Privacy Policies | Sitemap | Help | Contact Us